TITLE

Moving towards a new era in the management of chronic immune thrombocytopenia

AUTHOR(S)
Wadenvik, Hans; Olsson, Bob
PUB. DATE
July 2010
SOURCE
Annals of Hematology;Jul2010, Vol. 89, p87
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease in which a low concentration of plasma thrombopoietin (TPO) contributes to the thrombocytopenia. Functional thrombopoietin deficiency in response to thrombocytopenia is central to the pathophysiology of chronic ITP. Decreased platelet production in ITP patients has been described only in recent years, however. Following the development of TPO-mimetics, it has become clear that the augmentation of thrombopoiesis is a key therapeutic target. TPO mimetics are novel effective treatments providing durable platelet responses in ITP. Two agents have reached clinical practice, the 'peptibody' romiplostim (Nplate(R)) approved for treatment of thrombocytopenia in patients with chronic ITP in Europe, Canada, Australia and the USA and the non-peptide TPO mimetic, eltrombopag (Promacta(R)), approved in the USA. This review summarises the background to the development of these agents and presents an update on data from randomised phase III trials and open-label studies. These novel drugs provide a noteworthy treatment option for patients with chronic ITP, in whom thrombocytopenia and bleeding risk have not been controlled by standard treatments. The first candidates for treatment in clinical practice are undoubtedly refractory patients with lack of response to other therapies or at continued risk for bleeding despite treatment. Appropriate inclusion of TPO mimetics into the treatment paradigm will most likely have a positive impact on the long-term outcome of ITP and allow carefully monitored patients to remain well controlled, with good tolerability for prolonged periods.
ACCESSION #
52022212

 

Related Articles

  • Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne, Thomas; Imbach, Paul; Kühne, Thomas // Annals of Hematology;Jul2010, Vol. 89, p67 

    Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life. The condition has long been associated with an increased rate...

  • Hidden maternal autoimmune thrombocytopenia complicated by fetal subdural hematoma-case report and review of the literature. Rios, Lívia; Araujo Júnior, Edward; Nardozza, Luciano; Haratz, Karina; Moron, Antonio; Martins, Marília // Child's Nervous System;Jul2012, Vol. 28 Issue 7, p1113 

    The article presents case study of having subdural hematoma related to fetal autoimmune thrombocytopenia. It has been informed that a 35-year-old primigravida was referred for routine scan at 34 gestational weeks (GW) and a full-term boy was delivered by cesarean section at 39 GW with a...

  • Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Choung, Bum-Su; Yoo, Wan-Hee // Rheumatology International;May2012, Vol. 32 Issue 5, p1353 

    Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We...

  • The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune Thrombocytopenia. Lili Ji; Yanxia Zhan; Fanli Hua; Feng Li; Shanhua Zou; Weiguang Wang; Dongli Song; Zhihui Min; Hao Chen; Yunfeng Cheng // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Primary immune thrombocytopenia (ITP) is an autoimmune heterogeneous disorder that is characterized by decreased platelet count. Regulatory T (Treg) cells and T helper type 17 (Th17) cells are two subtypes of CD4+ T helper (Th) cells. They play opposite roles in immune tolerance and...

  • Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Salama, A.; Rieke, M.; Kiesewetter, H.; Depka, M.; von Depka, M // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p11 

    Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone and/or high-dose IVIgG are recommended for the emergency treatment of such patients with uncontrolled bleeding. However, some patients do...

  • Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Tamary, Hannah; Roganovic, Jelena; Chitlur, Meera; Nugent, Diane; Nugent, Diane J // Annals of Hematology;Jul2010, Vol. 89, p5 

    The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible. Therefore, the current management recommendations for ITP are largely dependent on clinical expertise and observations. As part of its discussions during...

  • Future research in ITP: an ICIS consensus. Zehnder, James L.; Semple, John W.; Imbach, Paul; Neufeld, Ellis J.; Buchanan, George R.; Cines, Douglas B.; ICIS Study Group on Future Research in ITP // Annals of Hematology;Jul2010, Vol. 89, p19 

    While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and...

  • Evaluating bleeding severity in immune thrombocytopenia (ITP). Neunert, Cindy E. // Annals of Hematology;Jul2010, Vol. 89, p47 

    Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe...

  • Editorial 3rd Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting in Basel, Switzerland, September 2009. Kühne, Thomas; Imbach, Paul; Kühne, Thomas // Annals of Hematology;Jul2010, Vol. 89, p1 

    The article presents information on the 3rd Intercontinental Cooperative Immune Thrombocytopenia (ITP) Study Group (ICIS) Expert Meeting, held during September 3-5, 2009, in Basel, Switzerland. The event was attended by more than 100 experts involved in basic science and clinical research. They...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics